Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Fred Alger Management LLC

Fred Alger Management LLC decreased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 5.1% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,243,717 shares of the company’s stock after selling 66,719 shares during the period. Fred Alger Management LLC’s holdings in Vaxcyte were worth $142,120,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of Vaxcyte by 68.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after purchasing an additional 8,685 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Vaxcyte by 392.4% during the second quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock worth $3,046,000 after buying an additional 32,149 shares in the last quarter. Natixis Advisors LLC increased its holdings in Vaxcyte by 61.1% in the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after buying an additional 8,606 shares in the last quarter. Tri Locum Partners LP acquired a new position in shares of Vaxcyte in the second quarter worth about $8,559,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Vaxcyte during the 2nd quarter worth about $1,053,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on PCVX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. Mizuho raised their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Leerink Partners upped their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Jefferies Financial Group increased their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, BTIG Research boosted their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $147.50.

Vaxcyte Stock Up 2.8 %

PCVX stock opened at $93.98 on Friday. Vaxcyte, Inc. has a 52-week low of $48.81 and a 52-week high of $121.06. The stock has a market cap of $11.71 billion, a price-to-earnings ratio of -20.43 and a beta of 1.01. The business has a fifty day moving average of $106.02 and a two-hundred day moving average of $90.00.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period last year, the company earned ($0.91) EPS. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Insider Activity

In other Vaxcyte news, SVP Mikhail Eydelman sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $109.27, for a total value of $546,350.00. Following the sale, the senior vice president now owns 28,623 shares of the company’s stock, valued at $3,127,635.21. The trade was a 14.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jim Wassil sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $111.93, for a total value of $1,119,300.00. Following the transaction, the chief operating officer now owns 207,503 shares in the company, valued at $23,225,810.79. This trade represents a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 102,464 shares of company stock valued at $11,455,576. Company insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.